Fibrocell Science — Investor Presentation (January 2017)
19 slides from Fibrocell Science's investor presentation, Jan 9, 2017
Slide 1: Corporate Presentation January 9, 2017
Corporate Presentation January 9, 2017
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu
Slide 3: Fibrocell at a Glance
Proprietary autologous fibroblast cell capabilities + Ex vivo genetic modification of patients’ own fibroblast cells FCX-007 Recessive Dystrophic Epidermolysis Bullosa (RDEB) FCX-013 Linear Scleroderma Arthritis and related conditions 3 Fibrocell at a Glance Personalized medical breakthroughs for di
Slide 4: Our Autologous Fibroblast Gene Therapy Platform
Autologous fibroblasts harvested from patients • Readily sourced, as fibroblasts are the most common cell type in skin and connective tissue • Reduced rejection and immunogenicity concerns because the donor is the patient • Established manufacturing process and regulatory pathway for autologous fibr
Slide 5: Personalized Biologics Approach
Personalized Biologics Approach 5
Slide 6: Development Pipeline
Development Pipeline 6 Personalized Biologic Condition Research Pre-Clinical Development Human Clinical Trials FCX-007 Recessive Dystrophic Epidermolysis Bullosa (RDEB) FCX-013 Linear Scleroderma Research Program Arthritis Human data expected 3Q17 IND filing expected 4Q17
Slide 7: FCX-007 Providing Hope for RDEB Patients
FCX-007 Providing Hope for RDEB Patients 7 RDEB patients do not produce type VII collagen (COL7) due to mutation in COL7A1 gene • Main component of anchoring fibrils that connect skin layers FCX-007 is an autologous human dermal fibroblast transduced with a lentiviral (LV) vector encoded for COL7A1
Slide 8: Recessive Dystrophic Epidermolysis Bullosa
Recessive Dystrophic Epidermolysis Bullosa 8 Disease Current Treatments Epidemiology • Cause: A mutation in the COL7A1 gene that encodes for COL7 • Devastating, progressive, painful blistering disease that often leads to death • Diagnosed at infancy • High mortality rate – 76% of RDEB suffers do not
Slide 9: Functional COL7 Expression Confirmation
Functional COL7 Expression Confirmation 9 Culture supernatant evaluated for in vitro COL7 expression • ELISA assay indicates virus dose-dependent protein expression • Trimeric form of COL7 produced by RDEB patient fibroblasts transduced with LV-COL7 •Must be trimeric to be functional Reference: Bruc
Slide 10: Detection of COL7 Expression by Immunofluorescence
10 Detection of COL7 Expression by Immunofluorescence (Magnification 20x) • In vitro COL7 expression noted from FCX-007 replicates (red) • FCX-007 expresses higher levels of COL7 than normal human dermal fibroblasts (NHDF) as depicted by a brighter signal • No expression of COL7 in RDEB-positive fib
Slide 11: Long-lasting COL7 Persistence Expected
11 Long-lasting COL7 Persistence Expected Fibroblast Cells • Autologous cells minimize rejection risk • Direct administration of FCX-007 to the upper dermis ensures COL7 is expressed in the basement membrane zone where anchoring fibrils are formed • Lower turnover rate than other skin cells such as
Slide 12: FCX-007 Phase I/II Clinical Trial Design
FCX-007 Phase I/II Clinical Trial Design 12 Title A Phase I/II Trial of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Objectives Primary 1) To evaluate the safety of FCX-007 Secondary 1) To evaluate mechanism of action of FCX
Slide 13: FCX-013 Development Progressing
FCX-013 Development Progressing 13 • Product profile Autologous fibroblasts genetically modified using lentivirus and encoded for a protein responsible for breaking down excess collagen Target protein known to breakdown collagens Incorporates Intrexon’s RheoSwitch Therapeutic System® (RTS®) to
Slide 14: FCX-013 employs Intrexon's RheoSwitch Therapeutic System
• FCX-013 employs Intrexon’s RheoSwitch Therapeutic System® (RTS®) The RTS® biologic switch is activated by an orally- administered activator ligand (AL) that provides the ability to control level and timing of protein expression • Enhances the safety profile of FCX-013 by providing control over t
Slide 15: Lead Indication: Linear Scleroderma
Lead Indication: Linear Scleroderma 15 Disease Epidemiology • Excess production of collagen characterized by skin fibrosis and linear scars • The linear areas of skin thickening may extend to underlying tissue and muscle in children which may impair growth in affected legs and arms or forehead • Les
Slide 16: FCX-013 Proof-of-Concept Study
FCX-013 Proof-of-Concept Study 16 • Study Design Bleomycin treated SCID mouse model N=30 mice over test and control groups Assessed histologically for reduction of dermal thickness and sub-dermal muscle in the presence of FCX-013 and oral ligand • Result Bleomycin treatment resulted in skin
Slide 17: Research Program for Arthritis
Research Program for Arthritis 17 • Deliver therapeutic protein locally to the joint providing sustained efficacy while avoiding key side effects typically associated with systemic therapy • Combines Fibrocell’s autologous fibroblast technology with Intrexon’s cellular engineering to develop localiz
Slide 18: Milestones and Financials
Milestones and Financials 18 Milestones Anticipated Timing FCX-007 1st Adult Subject Dosed 1Q17 (FCX-007 cells harvested, pre-dose testing in process) FCX-007 Phase I/II Trial First human clinical data 3Q17 FCX-013 IND Submission 4Q17 Financials • Cash = $21.3 million at 30 September 2016 (unaudited
Slide 19: References
References 1 Fritsch A., et. al. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanism of disease and response to fibroblast therapy. J Clin Invest.2008; 118:1669–1679. 2 Fine, J. et. al. (ed.). Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the
Fibrocell Science — Investor Presentation (January 2017) on 6ix